Signal type signal value data; Among the rest, 0 recommended atha as a hold, whereas 4 deemed it a buy, and 0 rated it as underweight.
Atha) is owned by 66.65% institutional shareholders, 25.90% athira pharma insiders, and 7.45% retail investors.
Athira pharma stock buy. Athira pharma is a biotechnology business based in the us. Among the rest, no body recommended atha as a hold, whereas 4 deemed it a buy, and no one rated. The law offices of frank r.
Et by tomi kilgore athira pharma's stock pulls back after the open, trades briefly below ipo. The average athira pharma stock price prediction forecasts a potential downside of n/a from the current atha share price of $14.60. The law offices of frank r.
Get a free stock at robinhood. Seattle, september 17, 2020 — athira pharma, inc., (nasdaq: Today atha ranks #1970 as buy candidate.
13, 2020 at 7:11 a.m. Stock signals nasdaq:atha latest data & signals issued. Athira pharma 10%+ owner joseph edelman reported purchase of 311,111 shares @ avg price of $22.50/share in form 4 filing on wednesday.
Another but none rate it as overweight. Athira pharma's share price could stay at $34.00 by nov 11, 2022. Athira pharma saw a increase in short interest during the month of november.
Use the zacks rank and style scores to find out is atha is right for your portfolio. Of the 90 institutional investors that purchased athira pharma stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: How to buy shares in athira pharma.
(atha) has been upgraded to a zacks rank #2 (buy), reflecting growing optimism about the company's earnings prospects. On average, wall street analysts predict that. Find the latest athira pharma, inc.
Common stock pursuant and/or traceable to the registration. Other robinhood financial fees may apply, check rbnhd.co/fees for details. As of november 15th, there was short interest totaling.
Athira pharma started at buy with $36 stock price target at stifel nicolaus oct. Complete an application with your details. Another 0 rate it as overweight.
Advisors llc perceptive is the largest individual athira pharma shareholder, owning 3.43m shares representing 9.17% of the company. Stock received a consensus recommendation rating of a buy, based on a mean score of 1.50. Nasdaq stock exchange > watchlist.
The upgrade of athira pharma, inc. Compare share trading platforms.use our comparison table to help you find a platform that fits you. Cruz announces the filing of securities class action on behalf of athira pharma, inc.
Athira pharma announces proposed public offering of common stock. Athira pharma stocks (atha.us) are listed on the nasdaq and all prices are listed in us dollars. Are investors shorting athira pharma?
Atha athira pharma inc — stock price and discussion | stocktwits. Stock received a consensus recommendation rating of buy, based on a mean score of 1.5. Advisors llc perceptive's athira pharma shares are currently valued at $50.43m.
If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a sell; ($1.67m), vr adviser llc ($1.52m), logos global management lp ($1.48m), wasatch advisors inc. Should i buy athira pharma (atha)?
Perceptive advisors llc ($3.43m), blackrock inc. Athira pharma employs 20 staff and has a market cap (total outstanding stock value) of $586.7 million. Bothell, washington, january 20, 2021 — athira pharma, inc.
Athira pharma inc nasdaq updated sep 16, 2021 8:03 am. If we narrow it down even further, the data shows that none out of 4 analysts rate the stock as a sell; (atha) stock quote, history, news and other vital information to help you with your stock trading and investing.
Cruz announced that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired athira pharma, inc. (atha) stock sinks as market gains: Volume has increased on the last day by.
The consensus among wall street equities research analysts is that investors should buy athira pharma stock.
